Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer

MeSH terms

• Aged
• Angiogenesis Inhibitors / administration & dosage*
• Angiogenesis Inhibitors / adverse effects
• Antibodies, Monoclonal, Humanized / administration & dosage*
• Antibodies, Monoclonal, Humanized / adverse effects
• Bevacizumab
• Breast Neoplasms / drug therapy
• Breast Neoplasms / pathology
• Cardiovascular Diseases / chemically induced
• Cardiovascular Diseases / epidemiology*
• Colorectal Neoplasms / drug therapy
• Colorectal Neoplasms / pathology
• Female
• Humans
• Incidence
• Male
• Neoplasm Metastasis
• Prognosis
• Prospective Studies
• Risk Factors